The identification and utilization of biomarkers such as matrix metalloproteinases (MMPs), urokinase plasminogen activator and its receptor (uPA/uPAR), myosin 5 A (MYO5A), survivin, and vascular endothelial growth factor (VEGF) have the potential to significantly enhance the prediction of pituitary tumor invasiveness. This evidence concerns the gene MYO5A and pituitary tumor.